← Back to Search

Cancer Vaccine

GRN-1201 + Pembrolizumab for Non-Small Cell Lung Cancer

Phase 2
Waitlist Available
Research Sponsored by BrightPath Biotherapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first dose through 16 weeks after last dose of study drug
Awards & highlights

Study Summary

This trial is testing a new combination treatment for advanced lung cancer. It is open to people who have not had treatment before, and who have a specific kind of genetic change in their cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first dose through 16 weeks after last dose of study drug
This trial's timeline: 3 weeks for screening, Varies for treatment, and first dose through 16 weeks after last dose of study drug for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assess the effect, as measured by response rate of the addition of GRN-1201 to Pembrolizumab
Secondary outcome measures
Clinical Benefit response rate (CR + PR + SD >/= 16 weeks)
Duration of clinical benefit
Duration of response in responding subjects
+4 more

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cohort 1Experimental Treatment1 Intervention
All subjects will have newly diagnosed, metastatic PD-L1+ (TPS ≥ 50%) NSCLC with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

Find a Location

Who is running the clinical trial?

BrightPath BiotherapeuticsLead Sponsor
1 Previous Clinical Trials
18 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What condition is it most common to see GRN-1201 + Pembrolizumab prescribed for?

"GRN-1201 in conjunction with pembrolizumab can be used to treat patients suffering from malignant neoplasms, unresectable melanoma, and microsatellite instability high."

Answered by AI

Are patients being accepted into this experiment at this time?

"As of right now, this clinical trial is not looking for new patients. According to the information found on clinicaltrials.gov, which was last updated on June 10th, 2022, this study was first posted on January 3rd, 2019. Although this specific trial may not be recruiting patients at the moment, there are over a thousand other trials that are currently seeking participants."

Answered by AI

What are the odds of developing an adverse reaction to GRN-1201 + Pembrolizumab?

"GRN-1201 + Pembrolizumab was given a safety score of 2 because, while there is data suggesting it is safe, none of the available information points to the efficacy of this combination treatment."

Answered by AI

Is this study prominent in North America?

"Currently, this trial is being conducted at 11 different sites. Some of these locations are in New Orleans, Metairie and Richmond with the other 8 located elsewhere. If you are considering participating in this study, it would be best to select a clinic closest to your location to reduce travel time commitments."

Answered by AI

How big is the pool of potential candidates for this clinical trial?

"This particular trial is no longer recruiting patients. The original posting date was January 3rd, 2019 and the most recent update was on June 10th, 2022. There are other studies that might be of interest; for example, there are 17 trials currently recruiting patients with malignant neoplasms and 1000 clinical studies involving GRN-1201 + Pembrolizumab that are looking for participants."

Answered by AI

Are there any other ongoing or completed research projects that have looked at GRN-1201 + Pembrolizumab?

"GRN-1201 + Pembrolizumab was first studied in the year 2010 at City of Hope. To date there have been 247 completed clinical trials. There are presently 1000 live trials, with a large number occurring in New Orleans, Louisiana."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC
2019. "GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03417882.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top